Literature DB >> 9426874

Progressive supranuclear palsy and corticobasal degeneration.

I Litvan1.   

Abstract

The clinical and neuropathological features characteristic of progressive supranuclear palsy and corticobasal degeneration are described in detail. These disorders are not as rare as previously believed, but are poorly recognized. In patients with parkinsonism, a high index of clinical suspicion, sometimes complemented by specific laboratory tests, should improve diagnostic accuracy. Biological treatments are at present not available, but suggested symptomatic therapies may improve the quality of life of patients with these disorders.

Entities:  

Mesh:

Year:  1997        PMID: 9426874

Source DB:  PubMed          Journal:  Baillieres Clin Neurol        ISSN: 0961-0421


  3 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

Authors:  Volker Welge; Oliver Fiege; Piotr Lewczuk; Brit Mollenhauer; Hermann Esselmann; Hans-Wolfgang Klafki; Stefanie Wolf; Claudia Trenkwalder; Markus Otto; Johannes Kornhuber; Jens Wiltfang; Mirko Bibl
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

3.  Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?

Authors:  B Mollenhauer; M Bibl; H Esselmann; P Steinacker; C Trenkwalder; J Wiltfang; M Otto
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.